Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Syenza News — health technology assessment, market access and health economics

Syenza's Top Picks

Latest News

obesity drug reimbursement in Portugal

Diseases

Obesity drug reimbursement in Portugal: new SNS terms

Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Illustration of a stone courthouse beside a clinic in a sunlit village square

Diseases Free account

Antiretroviral Tender Awards Declared Invalid by Pretoria Court

A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla’s review succeeded on all five grounds, while Hetero’s challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV

Syenza TeamRead ›
Intismeran adjuvant melanoma

Clinical Practice

Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%

Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess

Syenza TeamRead ›
neuroscience medical product development

Alzheimer's Disease

FDA Launches Neuroscience Medical Product Development Program

The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer’s Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Syenza TeamRead ›
clinical AI governance framework

Artificial Intelligence And Machine Learning

Clinical AI governance framework guides AI tool evaluation

A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.

Syenza TeamRead ›
palbociclib maintenance in HER2-positive breast cancer

Clinical Practice

Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal

Pfizer has withdrawn its EU application for palbociclib in HER2-positive breast cancer. EMA questioned the open-label PATINA endpoint.

Syenza TeamRead ›
Illustration of a village square with a woman speaking to older men at a table, musicians and a fruit seller

Clinical Practice

Health Economists in Clinical Trials: Why Early Engagement Matters

Health economists in clinical trials are most useful when they join early, explain their methods in plain language and plan for the data they will need. That was the central message of a webinar brought together by University College London and the Global Health Network at the University of Oxford. A professor of health policy and systems management in Uganda moderated three panelists with trial experience across Africa and Asia. Why trials need economic questions The moderator framed the session […]

Syenza TeamRead ›
Illustration of a patient waiting at a pharmacy counter as a new medicine box sits on the shelf

Big Data Analysis

New Drug Launch Prices Stay High While Patients Wait for Access

New drug launch prices are still high. ICER’s 2026 Launch Price and Access Report finds the median net price for 2025 approvals was about $257,000, and only about one in three new prescriptions was filled within 30 days. #SyenzaNews #MarketAccess #HEOR

Syenza TeamRead ›
CagriSema weight loss in women

Clinical Practice

CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1

Two post hoc REDEFINE 1 analyses show CagriSema weight loss in women held across premenopausal, perimenopausal and postmenopausal stages. #SyenzaNews #obesity #MarketAccess

Syenza TeamRead ›
ASPE finds Medicaid provider taxes raised employer premiums 1.5 to 1.7 percent. The 2025 WFTC law is projected to cut th

Health Policy Free account

Medicaid Provider Taxes Raise Private Insurance Premiums, ASPE Finds

ASPE finds Medicaid hospital provider taxes raised employer premiums 1.5 to 1.7 percent, and the 2025 WFTC law is projected to cut them further.

Syenza TeamRead ›

Value Science Weekly

The week in health technology assessment, market access and health economics — what moved, and what it means.

You can unsubscribe at any time. Read our privacy policy.

About this newsletter →

Search Intelligence